Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Zampedri

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Practical Neurology|March 14, 2024
Kennedy's diseaseHelen Devine, Matthew Solomons, Luca Zampedri, et al.
Journal of Parkinson'S Disease|May 31, 2018
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc AnalysisDilan Athauda, Kate Maclagan, Natalia Budnik, et al.
The European Journal of Neuroscience|August 3, 2018
Post hoc analysis of the Exenatide-PD trial-Factors that predict responseDilan Athauda, Kate Maclagan, Natalia Budnik, et al.
JCI Insight|July 8, 2024
Protein biomarker signature in patients with spinal and bulbar muscular atrophyAndrew Tn Tebbenkamp, Spencer B Huggett, Vittoria Lombardi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 3, 2019
Plasma pNfH levels differentiate SBMA from ALSVittoria Lombardi, Alessandro Bombaci, Luca Zampedri, et al.
Neurology|February 22, 2019
Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophyVittoria Lombardi, Giorgia Querin, Oliver J Ziff, et al.
Lancet (London, England)|August 8, 2017
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialDilan Athauda, Kate Maclagan, Simon S Skene, et al.
Neurology|August 9, 2019
Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severityUros Klickovic, Luca Zampedri, Christopher D J Sinclair, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Muscle MRI quantifies disease progression in amyotrophic lateral sclerosisUros Klickovic, Luca Zampedri, Nick Zafeiropoulos, et al.
Neurology|November 26, 2024
Functional Outcome Measures to Optimize Drug Development in Spinal and Bulbar Muscular Atrophy: Results From a Meta-Analysis of the Global SBMA DatasetSpencer B Huggett, Andrew T N Tebbenkamp, Carlo Rinaldi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Practical Neurology|March 14, 2024
Kennedy's diseaseHelen Devine, Matthew Solomons, Luca Zampedri, et al.
Journal of Parkinson'S Disease|May 31, 2018
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc AnalysisDilan Athauda, Kate Maclagan, Natalia Budnik, et al.
The European Journal of Neuroscience|August 3, 2018
Post hoc analysis of the Exenatide-PD trial-Factors that predict responseDilan Athauda, Kate Maclagan, Natalia Budnik, et al.
JCI Insight|July 8, 2024
Protein biomarker signature in patients with spinal and bulbar muscular atrophyAndrew Tn Tebbenkamp, Spencer B Huggett, Vittoria Lombardi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 3, 2019
Plasma pNfH levels differentiate SBMA from ALSVittoria Lombardi, Alessandro Bombaci, Luca Zampedri, et al.
Neurology|February 22, 2019
Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophyVittoria Lombardi, Giorgia Querin, Oliver J Ziff, et al.
Lancet (London, England)|August 8, 2017
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialDilan Athauda, Kate Maclagan, Simon S Skene, et al.
Neurology|August 9, 2019
Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severityUros Klickovic, Luca Zampedri, Christopher D J Sinclair, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Muscle MRI quantifies disease progression in amyotrophic lateral sclerosisUros Klickovic, Luca Zampedri, Nick Zafeiropoulos, et al.
Neurology|November 26, 2024
Functional Outcome Measures to Optimize Drug Development in Spinal and Bulbar Muscular Atrophy: Results From a Meta-Analysis of the Global SBMA DatasetSpencer B Huggett, Andrew T N Tebbenkamp, Carlo Rinaldi, et al.
Pageof 2